Botanical neurokinin inhibitor
Botanical neurokinin inhibitor has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jun 10, 2026: “Neurokinin pathway botanical antagonist for menopausal vasomotor symptoms: A randomized, double-blind, placebo-controlled study”.
1 paper studies it3 findingsUpdated
“BNI supplementation reduced VMS frequency by 2.2 hot flashes per day more than placebo (p = 0.003), corresponding to a 47.7% relative decrease.”
None of its findings points the other way.
- 1 lab in 2 countries
- Funder: Otsuka
- 3 of 3 findings with company ties
- Human trial1
Studies in people
1 study gave botanical neurokinin inhibitor to people and measured what changed.
down: Decreases vasomotor symptoms-2.2 hot flashes per day (-47.7%) vs placebo, p = 0.003
down: Decreases hot flash daily interferencep = 0.037
no change: Has no effect on serum estradiol
Randomized trial68 peopleWomen12 weeks
Postmenopausal women
Maturitas, Jun 10, 2026
What did studies of botanical neurokinin inhibitor find?
3Studies of botanical neurokinin inhibitor measured 3 outcomes; the most studied are serum estradiol (1 study), hot flash daily interference (1) and vasomotor symptoms (1).
Serum estradiol
no changein humans1
1 study
Serum estradiol
no changein humans1
Botanical neurokinin inhibitor showed no clear effect on serum estradiol in humans.
“No changes in serum estradiol or liver function abnormalities were detected.”
Human trial12 weeksn = 68
Maturitas
Hot flash daily interference
downin humans1
1 study
Hot flash daily interference
downin humans1
Botanical neurokinin inhibitor decreases hot flash daily interference in humans (p = 0.037).
“HFRDIS was improved in the BNI group (p = 0.037), with significant reduction on all subscales.”
Human trial12 weeksn = 68
Maturitas
Vasomotor symptoms
downin humans1
1 study
Vasomotor symptoms
downin humans1
Botanical neurokinin inhibitor decreases vasomotor symptoms in humans (-2.2 hot flashes per day (-47.7%) vs placebo, p = 0.003).
“BNI supplementation reduced VMS frequency by 2.2 hot flashes per day more than placebo (p = 0.003), corresponding to a 47.7% relative decrease.”
Human trial12 weeksn = 68
Maturitas